These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2567351)

  • 1. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L; Hansen L; Mørkeberg F; Gerlach J
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fuxe K; Werge T; Gerlach J
    Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.
    Casey DE; Bruhwyler J; Delarge J; Géczy J; Liégeois JF
    Psychopharmacology (Berl); 2001 Sep; 157(3):228-35. PubMed ID: 11605077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats.
    Iorio LC; Cohen M; Coffin VL
    J Pharmacol Exp Ther; 1991 Jul; 258(1):118-23. PubMed ID: 1830098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
    Casey DE
    Psychopharmacology (Berl); 1992; 107(1):18-22. PubMed ID: 1534177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys.
    Casey DE
    Psychopharmacology (Berl); 1995 Oct; 121(3):289-93. PubMed ID: 8584608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
    Batool F; Haleem DJ
    Pak J Pharm Sci; 2008 Oct; 21(4):411-20. PubMed ID: 18930864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-1 and D-2 receptor manipulation in Cebus monkeys: implication for extrapyramidal syndromes in humans.
    Gerlach J; Casey D; Kistrup K
    Clin Neuropharmacol; 1986; 9 Suppl 4():131-3. PubMed ID: 2952267
    [No Abstract]   [Full Text] [Related]  

  • 14. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1039-46. PubMed ID: 8099614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in cebus monkeys.
    Coffin VL; McHuch D; Chipkin RE; Barnett A
    Neurochem Int; 1992 Mar; 20 Suppl():141S-145S. PubMed ID: 1365413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
    Tidey JW; Bergman J
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates.
    Casey DE
    Psychopharmacol Bull; 1989; 25(3):457-9. PubMed ID: 2516634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms.
    Holson RR; Webb PJ; Grafton TF; Hansen DK
    Teratology; 1994 Aug; 50(2):125-36. PubMed ID: 7801300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.